by
The global buprenorphine market is primarily driven by the increasing prevalence of opioid addiction across the world. Buprenorphine is a partial opioid agonist used to treat opioid addiction by relieving withdrawal symptoms without producing euphoria. It is available in sublingual tablets, buccal films, and subdermal implants that deliver buprenorphine continuously. Buprenorphine provides an effective treatment for opioid use disorder by normalizing brain chemistry and blocking the euphoric effects of opioids without the risk of overdose or resale value. The rising awareness regarding opioid addiction and availability of generic versions of buprenorphine have increased its adoption rate in recent years.
The Global buprenorphine market is estimated to be valued at US$ 6367.1 Mn in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the buprenorphine market are Hyundai Heavy Industries (South Korea), Daewoo Shipbuilding & Marine Engineering (South Korea), China State Shipbuilding Corporation (China), Mitsubishi Heavy Industries (Japan), Samsung Heavy Industries (South Korea), Imabari Shipbuilding Co., Ltd. (Japan), Tsuneishi Group (Japan), China Shipbuilding Industry Corporation (China), General Dynamics Corporation (United States), Fincantieri S.p.A. (Italy), Meyer Werft GmbH & Co. KG (Germany), Navantia (Spain), Damen Shipyards Group (Netherlands), STX Offshore & Shipbuilding Co., Ltd. (South Korea), Kawasaki Heavy Industries (Japan). Growing prevalence of opioid addiction across major countries provides significant growth opportunities in the market. Key players are focusing on expanding their operations in high demand regions such as North America and Asia Pacific.
The global opioid crisis has opened opportunities for new and effective treatments such as buprenorphine. Generic availability and adoption of combination therapy with naloxone have favored its accessibility and adoption rate globally. Companies are collaborating with healthcare providers and governments to spread awareness regarding opioid addiction and benefits of buprenorphine treatment.
North America dominates the Global Buprenorphine Market Size owing to favorable reimbursement policies, rising cases of prescription opioid abuse, and availability of generic versions. However, Asia Pacific is expected to witness fastest growth during the forecast period supported by improving access to opioid addiction treatment in developing countries and supportive regulations.
Market Drivers
One of the major drivers for the growth of buprenorphine market is the rising prevalence of opioid addiction across the globe. According to National Institute on Drug Abuse, the global prevalence of opioid addiction disorder increased by 50% from 1990 to 2017. The growing cases of prescription opioid addiction in North America and Asia Pacific is a major factor boosting adoption of medications like buprenorphine for addiction management. Various awareness programs undertaken by government and private organizations regarding benefits of medication-assisted treatment are further supporting the market growth.
PEST Analysis
Political: Buprenorphine is a Schedule III drug under the Controlled Substances Act in the United States and is regulated by the US Drug Enforcement Administration. Regulations pertaining to its prescription, sale and use govern the market.
Economic: Rising Healthcare costs especially mental health and addiction treatment expenditure is driving demand for cost-effective treatment options like buprenorphine, supporting market growth. GDP growth and affordability also impact spending on opioid addiction treatment.
Social: Increasing rate of opioid addiction due to factors like misuse of prescription pain relievers is propelling demand for treatment drugs like buprenorphine. Growing social acceptance and awareness for medication-assisted treatment is boosting the market.
Technological: Advances in drug delivery systems and formulations like subdermal implants, buccal films and nasal sprays can improve patient compliance and treatment outcomes, benefitting the market. Research into new therapeutic applications and combinations can also expand the market scope over the forecast period.
The buprenorphine market in terms of value is concentrated majorly in North America where it originated. Countries like the United States account for the highest share due to high incidence of opioid use disorder, evolved healthcare infrastructure and favorable regulatory environment supporting widespread adoption of buprenorphine therapy.
The Asia Pacific region especially China, India and Japan is emerging as the fastest growing regional market for buprenorphine driven by rising opioid addiction rates, growing healthcare spending, increasing focus on substance use treatment and supportive regulatory framework being developed in key Asian countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
